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Abstract
Background: Epidemiological studies have found reduced health-related quality of life (QoL) in
patients with personality disorders (PDs), but few clinical studies have examined QoL in PDs, and
none of them are from an ordinary psychiatric outpatient clinic (POC). We wanted to examine
QoL in patients with PDs seen at a POC, to explore the associations of QoL with established
psychiatric measures, and to evaluate QoL as an outcome measure in PD patients.
Methods: 72 patients with PDs at a POC filled in the MOS Short Form 36 (SF-36), and two
established psychiatric self-rating measures. A national norm sample was compared on the SF-36.
An independent psychiatrist diagnosed PDs and Axis-I disorders by structured interviews and rated
the Global Assessment of Functioning (GAF). All measurements were repeated in the 39 PD
patients that attended the 2 years follow-up examination.
Results: PD patients showed high co-morbidity with other PDs and Axis I mental disorders, and
they scored significantly lower on all the SF-36 dimensions than age- and gender-adjusted norms.
Adjustment for co-morbid Axis I disorders had some influence, however. The SF-36 mental health,
vitality, and social functioning were significantly associated with the GAF and the self-rated
psychiatric measures. Significant changes at follow-up were found in the psychiatric measures, but
only on the mental health and role-physical of the SF-36.
Conclusion: Patients with PDs seen for treatment at a POC have globally poor QoL. Both physical
and mental dimensions of the SF-36 are correlated with established psychiatric measures in such
patients, but significant changes in these measures are only partly associated with changes in the
SF-36 dimensions.
Background
According to the DSM-IV [1] personality disorders (PDs)
are characterized by enduringly deviating patterns of per-
ceiving, relating to, and thinking about the environment
and oneself that are exhibited in a wide range of social and
personal contexts. Such patterns lead to "clinically signif-
icant distress or impairment in social, occupational, or
other important areas of functioning". The DSM-IV does
not indicate how "clinically significant distress or impair-
ment" (page 633) should be evaluated, however, and a
recent study showed that various formulations of this cri-
terion hardly increased diagnostic validity [2].
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Functioning Scale (GAF) as Axis V, it is reasonable to con-
sider if the GAF should be used for evaluations of "signif-
icant distress or impairment". Two problems are implicit
in such an approach: at what GAF cut-off score should
"significant distress or impairment" be set, and the evalu-
ation is only done by a professional. As to the first prob-
lem, Kessler et al [3] suggested a GAF score of 60 as a cut
off for "serious mental illness". As to the second, in
patients with somatic diseases "clinically significant dis-
tress or impairment" has for a long time been quantified
by self-rating of the health-related quality of life (QoL)
including mental health [4]. Several general instruments
for the rating of QoL have been developed among which
the Medical Outcome Study Short Form-36 (the SF-36)
and its brief version the SF-12 have become the most pop-
ular [5,6].
Major treatment outcome studies of PDs like the Collabo-
rative Longitudinal Personality Disorders Study [7], the
Norwegian Network of Psychotherapeutic Day Hospitals
[8], and the Cassel Hospital study [9] used the GAF, how-
ever, and did not included any QoL measurements, and
the QoL was not included in a recommended core battery
of instruments for measurement of changes in PD patients
[10].
In contrast, two epidemiological studies of PDs have used
the SF-12 as a measure of disability. In a national study
from Australia, Jackson and Burgess [11] reported that the
SF-12 Physical and Mental Component Summary Scales
(PCS and MCS) were both significantly reduced in per-
sons with one or more PDs diagnosed by a screening
instrument, compared to persons without. When further
examining the relationship between the SF-12 and PDs,
they found that co-morbid Axis I and chronic physical
conditions explained a considerable part of the MCS and
PCS scores in PDs [12]. Mean MCS and PCS scores also
became significantly lower with an increasing number of
comorbid PDs present. A national study from the United
States [13] confirmed the reduced MCS after controlling
for co-morbid Axis I disorder in the avoidant, dependent,
paranoid, schizoid, and antisocial PDs, but not in the his-
trionic PD, diagnosed by a more extensive diagnostic
interview schedule than the Australian study.
A review of the literature showed that the QoL had only
been used as a disability measure in a few clinical research
studies of PD patients. In depressed elderly patients,
Abrams et al [14] found that the presence of criteria for
cluster B PDs predicted lower QoL. Since the cluster B cri-
teria overlapped considerably with symptoms of depres-
sion, it was unclear if they made any independent
contribution to reduced QoL. Swinton et al [15] reported
that male PD patients in a high security forensic setting
were less satisfied with their overall QoL than patients
with schizophrenia. The authors emphasized that the
high security setting was quite unusual. Hueston et al.
[16] showed that primary care patients with high risk for
PDs, scored significantly lower on overall QoL and on sev-
eral subscales of the SF-36, compared to patients with a
low risk for PDs. Since prevalence of depression and alco-
hol dependence was higher in the high-risk group, the
influence of PDs alone on QoL was difficult to tease out
in that study. Nakao et al [17] examined the relationship
between PDs and the GAF in 136 Axis I patients mainly
with mood and anxiety disorders and found that patients
with any comorbid PDs were more disabled than those
without. They did not adjust for the presence of Axis I dis-
orders, however.
None of these clinical studies takes QoL as observed in PD
patients seen at an ordinary psychiatric outpatient clinic
(POC) as their point of departure. However PD patients
are frequent at POC, and the QoL is an important self-
rated measure of "clinically significant distress or impair-
ment". Since QoL data on PD patients seen at at POC
seems to be lacking from the literature, we found it rele-
vant to study a consecutive sample of PD patients from a
POC and collect QoL data with SF-36. We posed the fol-
lowing research questions: 1) How are the SF-36 dimen-
sions mean scores in PD patients compared to age- and
gender-adjusted norm data? 2) To what extent are the SF-
36 scores in PD patients associated with co-morbid Axis I
disorders? 3) How is the association between the SF-36
dimension and established patient- and professional-
rated psychiatric measures in PD patients? and 4) What
changes in the SF-36 dimensions of treated PD patients
are observed from baseline to follow-up, and how are they
related to changes in the psychiatric measures?
Methods
Setting
Furuset POC serves a communality of Oslo City, Norway
with a population of 28.000 people. At the time of the
study, the staff consisted of three psychiatrists, three clin-
ical psychologists, two psychiatric nurses, and two social
workers. The intake rate was approximately 400 new
patients a year. The first author (KN) invited the staff to
take part in the study by referring to her new patients with
probable PDs. Six professionals were willing to partici-
pate, while four declined due to heavy clinical burden, or
lack of interest.
At the start of the study in 1996, Furuset was a new suburb
of Oslo, and the inhabitants were characterized by lower
socio-economic conditions, high mobility, and a consid-
erable prevalence of immigrants from Asian countries.
The suburb had a high proportion of municipal housings,
and the criterion for allotment to them was severe mentalPage 2 of 12
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patients seen at Furuset POC were out of work due to
mental disorders, and/or due to socio-economic
circumstances.
Patients
Patients aged from 18 to 75 years were consecutively
recruited from January 1, 1996 to June 30, 1998. The
patients were referred from the local GPs, and physical
examination and adequate treatment and follow-up of
physical diseases were the responsibility of the GPs. The
six therapists screened for probable PDs among new
patients scheduled for treatment. Exclusion criteria were
mental retardation, lifetime psychosis and bipolar disor-
der, organic mental disorders, current strong suicidal ide-
ation, and insufficient knowledge of the Norwegian
language. Eligible patients received oral and written infor-
mation about the study from their therapists. Then the
patients were invited to take part in the study, and they all
gave written informed consent. The Ethical Review Board
of Department of Psychiatry, Aker University Hospital
approved the project.
The six therapists did not miss out any patients at screen-
ing, but 5 (4%) eligible patients declined to take part in
the study. Among 110 eligible patients referred to the
study, only 91 filled in the SF-36 at baseline due to admin-
istrative misunderstandings. However, when they were
compared to the 19 who did not fill in, the non-attenders
only had significantly fewer co-morbid Axis I-disorders
(data not shown).
In order to answer the research questions, the sample was
divided into three groups: cluster A+B PDs (n = 39), clus-
ter C (n = 33), and Axis I-disorders (n = 19). The cluster
A+B group could also contain co-morbid cluster C PDs
and Axis I-disorders, and the cluster C co-morbid Axis I-
disorders.
Follow-up procedure
Two years after baseline, the patients received a mailed
written appointment for a follow-up interview. Those
who did not show up were sent a written reminder. If they
still did not meet, they were called by phone, and if there
was no answer, their addresses and phone numbers were
checked at the Census register. Appointments were mailed
to new addresses, and phone-calls were made in case of
non-response. Only a few patients responded to these
extended search procedures.
Norm sample
Norm data on the SF-36 was obtained from the Survey of
Level of Living in Norway 1998 [18] comprising 6.638
participants aged 23 to 75 years. The norm data were
adjusted by gender and distribution into 5-year age
groups in relation to the PD sample.
Assessments
At baseline, diagnoses of PDs were made with the use of
the Personality Disorder Examination, and Axis I-disor-
ders were diagnosed by the MINI-International Neuropsy-
chiatric Interview. Anamnestic data were collected, and
global assessment of function was rated. The professional-
based interviews and examinations of all patients at base-
line and follow-up were carried out by a single experi-
enced psychiatrist (KN), who did not take part in any
treatment given.
All patients also filled in the following self-rating instru-
ments at baseline: the SF-36, the Social Adjustment Scale,
and the Symptom Checklist 90-Revised Personality Sever-
ity Index.
At follow-up all these assessments were repeated, and
additional information about treatment as well as job/
education, social- and family changes was collected.
Measures
Professional-rated
The Personality Disorder Examination (PDE) [19] is a struc-
tured clinical interview for PDs according to the DSM-III-
R with good inter-rater reliability, and wide international
application. Findings are reported as PD diagnoses, and as
dimensional PD scores based on the sum of the scoring on
each PD criterion (0: not present, 1: probably present, and
2: definitely present). Dimensional scores for the PD clus-
ters are used as a main psychopathology variable, and the
numbers of PDs are also reported.
The MINI International Neuropsychiatric Interview [20] was
used to diagnose Axis-I disorders according to DSM-IV.
The MINI covers 18 Axis-I disorders, has been translated
into many languages and has demonstrated good inter-
rater reliability. Findings are reported as numbers and per-
centages of patients with positive Axis-I diagnoses, and as
mean number of such diagnoses.
The Global Assessment of Functioning (GAF) is a rating scale
for the current evaluation of the overall functioning of a
subject on a continuum from severe mental disorder to
complete mental health that was defined as Axis V of the
DSM-IV. Scale values range from 1 (sickest individual) to
100 (the healthiest person). The scale is divided in ten
equal intervals from 1 – 10 to 91 – 100. Most outpatients
will be rated between 40 and 70, although some individ-
uals rated above 70 may seek therapy. The GAF is a relia-
ble instrument [21], and the cut-off score for 'minimal
impairment' has been set at 70 points or higher [22] and
for 'serious mental disorder' at lower than 60 [3].Page 3 of 12
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The SF-36 [5] was chosen for measurement of health-
related QoL, since it is in widespread use, and has shown
good psychometric properties in Norway [23]. The SF-36
has demonstrated sensitivity to change, and score changes
can be interpreted as changes in the health-related quality
of life of the patient. The SF-36 assesses eight dimensions
of physical and mental health, and the range is from 100
(optimal) to zero (poorest): physical functioning (PF),
physical role functioning (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), emo-
tional role functioning (RE), and mental health (MH).
The Social Adjustment Scale (SAS-SR) [24] contains 42
questions which investigate expressive or instrumental
roles in six major areas of functioning: work, social and
leisure activities, relationship with extended family, role
as a spouse/ partner, role as a parent, and role as member
of the family unit. Each area is measured as a continuous
variable, and the scales for individual items range from 1
(best) to 5 (worst). The scores within each role area are
summed, and a mean for each area is obtained. By adding
up the scores of all items and dividing by the number of
items actually scored, an overall adjustment score is
obtained.
The Symptom Checklist 90-Revised (SCL-90-R), Personality
Severity Index (PSI). The SCL-90-R is a 90-item self-report
inventory assessing current levels of mental symptoms
patterns. Each item is a description of a mental symptom
rated on a five-point scale, and rates the degree of 'dis-
tress/discomfort' during the last week prior to its adminis-
tration. Several indices based on the SCL-90-R scores have
been defined, and the PSI is the mean value of 22 items
covering the interpersonal sensitivity, anger/ hostility, and
paranoid ideation subscales. The PSI reflects the presence
and severity of relatively enduring characteristics of the
patient, and is, therefore, relevant for the evaluation of
severe PDs [25]. For the PSI, pathology is defined by a cut-
off score of ≥ 1.0.
Statistics
Data were analyzed by SPSS version 12.0. Descriptive sta-
tistics were conducted with independent and paired-sam-
ple t-test as well as one-way ANOVA (with Bonferroni's
correction for multiple comparisons) for metric variables,
and with χ2 and Fisher's Exact Test for categorical varia-
bles. The Mann-Whitney test and the Wilcoxon signed-
rank test were applied for metric variables when the data
distribution violated parametric assumptions. Spearman's
rank correlation was used for associations. One-sample t-
tests were applied when the SF-36 dimension scores of the
age- and gender-adjusted norm groups were compared to
the means of the three diagnostic groups. The comparison
of mean scores on the SF-36 dimensions between the
three groups was conducted with oneway ANOVA with
Bonferroni's correction. The influence on the QoL scores
of patients with PDs of Axis I disorders and of cluster C
PDs in the cluster A+B PDs group, was examined with lin-
ear regression analyses. All tests were two-sided, and the
level of significance was set at p < .05.
Results
Sample characteristics
All the 91 patients included were Caucasian, and 48
(53%) were females. The mean age of the sample at base-
line was 36.3 years (SD 10.5) and ranging from 19 to 74
years, with a median of 35 years. None of the patients had
any significant somatic diseases as reported by their GPs.
Patients belonging to the cluster A+B, cluster C, and Axis
I- disorders groups did not differ at baseline on demo-
graphic variables (Table 1).
As to psychopathology, the Cluster A and B PDs criteria
sum scores were significantly higher in the Cluster A+B
group compared to the two other groups, and both cluster
A+B and cluster C group had significantly higher scores on
cluster C criteria sum score than the Axis I group (Table 1).
The Cluster A+B group had significantly lower GAF-score
and higher PSI score than the two other groups which did
not differ from each other. Mental problems had started
significantly earlier in the PD groups compared to the Axis
I-group. The SAS Overall adjustment was significantly
poorer in the cluster A+B and cluster C groups, compared
to the Axis I group.
The diagnostic distribution of PDs and Axis I disorders in
the three groups at baseline and follow-up are given in
Table 2. The mean number of PDs diagnosed in cluster
A+B was 2.2, and in cluster C 1.3 per patient, and the most
common PDs were avoidant, borderline, and dependent.
One PD was observed in 37 patients (51%), two PDs in 20
(28%), and three PDs in 15 patients (21%). Fifty-four
(75%) of the PD patient had at least one co-morbid Axis
I-disorder.
Axis-I disorders were equally common in the two PD
groups (mean 1.5 disorder) and with slightly lower mean
(1.2) in the Axis I-disorder group. Depressions, anxiety
disorders, and alcohol dependence were the most fre-
quent Axis I diagnoses in all groups.
QoL in PD patients
Figure 1. shows that the mean scores on the eight dimen-
sions of the SF-36 of the PD patients at baseline are signif-
icantly lower (p < .001 for all) than those of the age- and
gender-adjusted norms. The mean difference was least (13
points) for PF, and highest for RF and RE (54 points and
49 points, respectively).Page 4 of 12
(page number not for citation purposes)
BMC Psychiatry 2005, 5:10 http://www.biomedcentral.com/1471-244X/5/10Table 1: Demographic and psychopathological features at baseline in patients with cluster A+B, and cluster C personality disorders, 
and non-psychotic Axis I disorders.
Variables Cluster A+B (n = 39) Cluster C (n = 33) Axis I (n = 19) p
Age (mean, SD) 35.1 (11.2) 36.6 (10.9) 41.1 (10.4) .15
Gender (n, %) .74
Male 17 (44) 17 (52) 8 (42)
Female 22 (55) 16 (48) 11 (58)
Relationship (n, %) .53
Paired 23 (59) 18 (55) 7 (37)
Non-paired 16 (41) 15 (45) 12 (63)
Basic education level (n, %) .28
≤ 9 years 15 (33) 13 (32) 8 (33)
10 – 12 years 14 (31) 16 (39) 13 (54)
≥ 13 years 16 (36) 12 (29) 3 (13)
Early childhood loss (n, %) 12 (31) 7 (21) 1 (5) .22
Childhood sexual abuse (n, %) 7 (18) 7 (21) 1 (5) .22
Age of onset mental problems (mean, SD) 16.7 (8.9) 20.0 (8.4) 27.0 (11.8) <. 001 A+B, C vs Axis I
Work income (n, %) 23 (59) 21 (64) 13 (68) .78
Economic support 16 (41) 12 (36) 6 (32)
Income last year (1.000 NOK) (mean, SD) 154 (74) 178 (70) 179 (62) .27
On sickleave last year (n, %) .37
No 18 (46) 10 (30) 5 (26)
≤ 12 weeks 11 (28) 12 (37) 5 (26)
≥ 13 weeks 10 (26) 11 (33) 9 (52)
No of PD cluster criteria (mean, SD)
Total 41.8 (16.2) 26.6 (11.9) 8.1 (9.2) < .001 A+B vs C vs Axis I
Cluster A 11.3 (8.2) 5.6 (4.6) 1.6 (2.0) < .001 A+B vs C, Axis I
Cluster B 14.7 (10.9) 4.8 (5.4) 2.6 (3.7) < .001 A+B vs C, Axis I
Cluster C 15.8 (10.0) 16.2 (5.7) 3.9 (5.4) < .001 A+B, C vs Axis I
Comorbid Axis I disorder (n, % .60
No 10 (26) 8 (24) -
Yes 29 (74) 25 (76)
GAF (mean, SD) 41.5 (9.1) 51.0 (7.4) 55.4 (9.3) < .001 A+B vs C, Axis I
PSI (mean, SD) 1.80 (.78) 1.24 (.71) 1.24 (.81) .005 A+B vs C, axis I
SAS (mean, SD) Overall adjustment 2.70 (.66) 2.59 (.59) 2.16 (.52) .007 A+B, C vs Axis I
Work 2.86 (1.62) 3.01 (1.80) 2.07 (.50) .94
Social and leisure 3.18 (1.18) 2.96 (1.06) 2.44 (.91) .06
Extended family 2.29 (.60) 2.00 (.51) 1.95 (.68) .05
Marital, partnership 2.21 (.56) 2.59 (.78) 2.14 (.63) .10
Parental 2.00 (.66) 1.91 (.58) 1.52 (.67) .14
Family unit 2.17 (.96) 2.21 (.95) 2.10 (.81) .94Page 5 of 12
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morbid Axis I disorders reduced the PF, GH, VT, SF, and
MH scores of the total PD group significantly. Controlling
for comorbid cluster C PDs did not influence the SF-36
scores of the cluster A+B PDs to any significant extent,
while control for Axis disorders significantly reduced the
MH scores in the cluster A+B and cluster C groups.
No significant differences were found between genders on
any of the SF-36 dimensions among the PD patients (data
not shown). Both the cluster A+B, the cluster C, and the
Axis I group differed significantly from their norms on all
eight SF-36 dimensions (data not shown). No significant
differences were observed on the eight SF-36 dimensions
between the three diagnostic groups (Figure 2).
When we compared the patients with one (n = 37), two (n
= 20), and three or more (n = 15) PDs, we did not observe
any significant differences in mean MCS and PCS scores.
Correlation between SF-36 dimensions and other measures
The eight dimensions of SF-36 are regularly divided into
the four physical: PF, RP, BP, and GH, and the four mental
ones: VT, SF, RE, and MH. In our PD sample the SF-36
mental dimensions had most significant correlations with
the psychiatric measures of the GAF, the SCL-90-R PSI, the
sum of positive PDs diagnostic criteria, and the dimen-
sions of the SAS (Table 3). The SF-36 MH had a significant
correlation to most of these measures, followed by VT and
SF. The physical dimensions of the SF-36 had less fre-
quently a significant correlation to the psychiatric
measures.
The SAS overall adjustment and the SAS social and leisure
functioning had significant correlations to all the SF-36
dimensions, while the SAS marital/ partnership and the
SAS parental functioning had none. The SAS work,
extended family, and family unit fell in between.
Table 2: Diagnostic distribution of the baseline and follow-up samples.
Baseline Follow-up
Cluster A+B 
(n = 39)
Cluster C 
(n = 33)
Axis I 
(n = 19)
Cluster A+B 
(n = 18)
Cluster C 
(n = 21)
Axis I 
(n = 11)
Personality disorders (DSM-III-R) N (%) N (%) N (%) N (%) N (%) N (%)
Paranoid 14 (36) - - 7 (39) 2 (10) 1 (9)
Schizotyp 6 (15) - - 2 (11) 1 (5) -
Schizoid 4 (10) - - 4 (22) - -
Antisocial 4 (10) - - 1 (6) - -
Narcissistic 0 (0) - - 0 (0) - -
Histrionic 4 (10) - - 0 (0) - -
Borderline 19 (49) - - 2 (11) - -
Dependent 5 (13) 7 (21) - 1 (6) 3 (14) -
Avoidant 15 (39) 25 (76) - 11 (61) 15 (71) 3 (27)
Obsessive-compulsive 5 (13) 8 (24) - 1 (6) 2 (10) -
Passive-aggressive 8 (21) 2 (6) - 1 (6) 2 (10) -
Mean no of PDs 2.2 1.3 - 1.7 1.2 .4
Axis I disorders (DSM-IV)
Major depression 6 (15) 9 (27) 3 (16) 0 (0) 1 (5) 1 (9)
Dysthymia 5 (13) 11 (33) 5 (26) 4 (22) 4 (19) 1 (9)
Panic disorder 7 (18) 7 (21) 2 (11) 0 (0) 2 (10) 1 (9)
Agoraphobia 5 (13) 7 (21) 2 (11) 2 (11) 2 (10) 2 (18)
Social phobia 9 (23) 8 (24) 2 (11) 2 (11) 4 (19) 1 (9)
GAD* 1 (3) 0 (0) 2 (11) 0 (0) 0 (0) 0 (0)
OCD* 4 (10) 2 (6) 2 (11) 0 (0) 0 (0) 1 (9)
Alcohol dependence 10 (26) 2 (6) 3 (16) 1 (6) 0 (0) 2 (18)
Substance dependence 7 (18) 0 (0) 2 (6) 0 (0) 1 (5) 0 (0)
Bulimia nervosa 4 (10) 1 (3) 0 (0) 0 (0) 1 (5) 0 (0)
PTSD* 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0)
Mean no of Axis I disorders 1.5 1.5 1.2 .5 0.7 0.8
*GAD: Generalized anxiety disorders, OCD: Obsessive-compulsive disorder, PTSD: Post-traumatic stress disorderPage 6 of 12
(page number not for citation purposes)
BMC Psychiatry 2005, 5:10 http://www.biomedcentral.com/1471-244X/5/10What changes in the QoL of PD patients can be observed 
from baseline to follow-up two years later?
Although quite intensive search for patients was done for
the follow-up examination, only 50 patients (53%) of the
91 patients who rated themselves on the SF-36 complied.
The distribution of patients were cluster A+B group (n =
18), cluster C (n = 21), and Axis I-disorder group (n = 11).
Due to small sample sizes, the Axis I disorder was dropped
from further analysis and the two PD groups were pooled
as to the study of changes after treatment. The 39 PD
patient with SF-36 ratings both at baseline and follow-up
were compared to the 33 PD patients only seen at
SF-36 mean dimensional scores in personality disorder sample (N = 72) and the age- and gender-adjusted norm sampleFigure 1
SF-36 mean dimensional scores in personality disorder sample (N = 72) and the age- and gender-adjusted norm sample.
SF-36 mean dimensional scores at baseline for Cluster A+B, Cluster C, and Axis I-disorders groupsFigure 2
SF-36 mean dimensional scores at baseline for Cluster A+B, Cluster C, and Axis I-disorders groups.
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dimensions of Social Adjustment Scale (SAS).
PF RP BP GH VT SF RE MH
GAF .12 .32** .02 .32** .26* .36** .30** .40**
Total no of positive PD criteria .03 -.11 .02 -.27** -.14 -.18 -.05 -.26**
SCL-90-R PSI -.22* -.17 -.12 -.26* -.25* -.34** -.19 -.38**
SAS Overall -.38** -.31** -.23* -.34** -.42** -.45** -.30** -.45**
SAS Work -.17 -.22* -.10 -.16 -.44** -.31* -.26* -.41**
SAS Social and leisure -.30** -.35** -.24* -.32** -.43** -.39** -.29** -.37**
SAS Extended family -.20 -.18 -.23* -.21 -.26* -.32* -.28* -.43**
SAS Marital/partner -.18 .01 -.04 -.18 -.24 -.08 -.05 -.10
SAS Parental -.04 -.06 .06 .02 -.07 -.09 -.07 -.04
SAS Family unit -.38** -.22 -.26* -.20 -.37** -.31* -.27* -.35**
Sum significant correlation 4 4 4 4 6 7 6 8
* Correlation is significant at the .05 level (two-tailed), ** Correlation is significant at the .01 level (two-tailed)
Table 4: Demographic, psychopathological, and treatment features at baseline for patients with personality disorders with (N = 39) 
and without (n = 33) follow-up examination.
Variable Follow-up + (n = 39) Follow-up - (n = 33) p
Age (mean, SD) 37.9 (11.6) 33.3 (9.9) .08
Gender (n, %) .50
Male 17 (44) 17 (52)
Female 22 (56) 16 (48)
Relationship (n, %) .56
Paired 18 (46) 13 (39)
Non-paired 21 (54) 20 (61)
Basic education level (n, %) .64
≤ 9 years 11 (29) 13 (40)
10 – 12 years 13 (34) 10 (30)
≥ 13 years 14 (37) 10 (30)
≥ 1 cluster A PDs 13 (33) 6 (18) .15
≥ 1 cluster B PDs 10 (26) 15 (45) .08
≥ 1 cluster C PDs 35 (90) 22 (67) .02
Mean (SD) of PD cluster criteria
Total 34.8 (17.9) 34.8 (14.3) .99
Cluster A 9.5 (8.7) 7.7 (5.1) .28
Cluster B 7.6 (9.3) 13.1 (10.3) .02
Cluster C 17.6 (8.9) 14.0 (7.2) .07
≥ 1 depressive disorder 19 (49) 7 (21) .02
≥ 1 anxiety disorder 17 (44) 16 (49) .68
≥ 1 substance use disorder 9 (23) 11 (33) .33
Comorbid Axis I disorder (n, %) .79
No 9 (23) 9 (27)Page 8 of 12
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and among the non-compliant patients those with bor-
derline PD, and alcohol and substance dependence were
over-represented.
Few significant differences were observed between com-
pliant and non-compliant PD patients at follow-up (Table
4). In particular, no significant differences of the eight SF-
36 dimensions were observed between the compliers and
non-compliers at baseline. The compliers had signifi-
cantly more depressive disorders and cluster C PDs at
baseline. All of those who terminated treatment without
the consent of their therapist (N = 22) were in the non-
compliant group. The non-compliant patients also had a
significantly longer mean duration of treatment. The
mean treatment time for the PD patients attending follow-
up was 16.6 months (SD 5.9), median 18 months, and
range 4 to 24 months, and the mean follow-up time since
treatment termination was 9.8 months (SD 6.4), median
10.4 months, and range 0 to 26 months. The majority of
the patients had weekly individual psychotherapy,
although a small proportion also had group psychother-
apy in addition. Drug treatment was given to 20 patients
of the 39 patients, and to 20 of the 33 non-compliers (ns).
Among those seen at follow-up, had 15 got antidepressive
and 5 antipsychotic medication, in addition to
psychotherapy.
In the 39 PD patients who complied at both baseline and
follow-up, significant improvement was seen in the RF
and MH dimensions of the SF-36, while considerable, but
non-significant changes were observed for BP and SF
(Table 5).
Both professional-rated measures the GAF, and the mean
total number of PD criteria, showed significant improve-
ment. Among the patient-rated measures significant better
results at follow-up were found for the SCL-90-R PSI, the
SAS overall adjustment, and the SAS social and leisure
scales.
Discussion
The main findings of this study of mainly co-morbid PD
patients treated at an ordinary POC, was that the QoL on
both the physical and mental SF-36 dimensions was sig-
nificantly lower than that of an age- and gender-adjusted
general population sample. According to our knowledge,
ours is the first report on QoL-data in such PD patients at
a POC. This finding is in accordance with QoL studies of
PD patients in the general population [11,13], and
Yes 30 (77) 24 (33)
GAF (mean, SD) 46.0 (9.4) 45.7 (9.9) .91
PSI (mean, SD) 1.5 (.9) 1.6 (.7) .85
SAS Overall (mean, SD) 2.7 (.6) 2.6 (.6) .86
SF-36 (mean, SD)*
Physical Functioning 79.4 (19.1) 76.7 (22.5) .72
Role Functioning 31.4 (34.3) 25.8 (36.2) .27
Bodily Pain 47.6 (28.9) 48.1 (26.7) .71
General Health 51.4 (23.5) 50.5 (20.39 .99
Vitality 35.0 (19.6) 29.1 (18.6) .16
Social Functioning 45.2 (28.5) 48.9 (21.5) .60
Role Emotional 42.7 (39.7) 32.3 (31.7) .35
Mental Health 42.5 (23.2) 38.3 (19.5) .52
No of sessions (mean, SD)* 16.6 (5.9) 18.8 (26.9) .01
Termination without consensus (n, %) 0 (0.0) 22 (67) < . 001
Treated by specialist (n, %) 14 (36) 16 (49) .28
Additional drug treatment (n, %) 20 (51) 20 (61) .43
*Mann-Whitney tests
Table 4: Demographic, psychopathological, and treatment features at baseline for patients with personality disorders with (N = 39) 
and without (n = 33) follow-up examination. (Continued)Page 9 of 12
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anxiety disorders, depression, schizophrenia, and sub-
stance dependence [27-30]. However, the SF-36 dimen-
sion mean scores of our PD sample are lower than those
reported for these diagnoses, and for co-morbid disorders
[31]. In our sample we did not find any significant
differences between the SF-36 dimension scores of the
cluster A+B, cluster C, or Axis I groups, and all groups had
significantly lower scores on all dimensions than their
age- and gender-adjusted norm groups.
In contrast to the epidemiological study from Australia
[12] we did not find worsening of MCS and PCS with
increasing number of PDs present in our sample. This
could be due to our small samples, but also due to the fact
that our patients with 1 PD had considerably lower QoL
than in the Australian survey [MCS: 33.7 (SD 10.6) versus
44.4 (SD 12.0), p < .001, and PCS: 43.8 (SD 8.6) versus
46.9 (SD 11.0), p = .03].
Comorbid Axis I disorders explained a significant part of
scores of PF, GH, VT, SF, and MH scores of the total PD
group. This is in accordance with the findings of the Aus-
tralian study [12].
We found that the SF-36 dimensions had variable associ-
ations with established psychiatric measures. As expected
the SF-36 MH was most strongly associated with the psy-
chiatric measures, but so were also SF and VT. For the SAS
we found that overall adjustment and social and leisure
activities were significantly correlated to all the SF-36
dimensions. In our PD sample we observed a somewhat
different pattern of significant correlations between the
GAF and the SF-36 dimensions than reported by Meijer et
al. [32] in patients with schizophrenia. Small sample sizes
and different diagnostic classes could be the explanation.
However, in sum the SF-36 had a considerable association
with established psychiatric measures in our PD sample.
For both the patient- and professional-rated psychiatric
measures significant changes at follow-up after treatment
was observed in the 39 patients who also scored them-
selves on the SF-36. We cannot say if these changes were
related to treatment, and ours is not an outcome study.
We wanted to examine if changes in established psychiat-
ric measures were associated with changes in the QoL
measured by the SF-36 in the PD patients seen at a POC.
Significant changes at follow-up were found for only two
of the SF-36 dimensions, however, one physical (RP) and
one mental (MH). While the finding for MH was
expected, the change in RP which covered problems with
work or other daily activities as a result of physical health
was more difficult to explain. The score on that dimension
was extraordinarily low at baseline (mean 31.4), and
regression towards mean could be a likely explanation. It
seemed that only MH of the SF-36 changed in the same
way as established psychiatric measures in our study. The
Table 5: Changes from baseline to follow-up in patients with personality disorders (n = 39).
Measure Baseline Mean (SD) Follow-up Mean (SD) P
SF-36
Physical Functioning 79.4 (19.2) 76.8 (24.6) .95
Role Physical 31.4 (34.3) 51.3 (38.5) .01
Bodily Pain 47.6 (28.9) 57.5 (25.6) .06
General Health 51.4 (23.5) 56.0 (26.6) .22
Vitality 35.0 (19.6) 36.3 (21.4) .70
Social functioning 45.2 (28.5) 53.5 (28.7) .09
Role-emotional 42.7 (39.7) 41.9 (38.0) .89
Mental Health 42.5 (23.2) 50.1 (22.3) .03
Global Assessment of functioning 46.0 (9.4) 54.6 (9.6) < .001
Total no of PD criteria 34.8 (17.9) 25.7 (11.5) < .001
SCL-90-R PSI 1.52 (.86) 1.30 (.80) .035
Social Adjustment Scale (SAS)
Overall adjustment 2.66 (.63) 2.42 (.62) .007
Work 2.76 (1.49) 2.36 (1.39) .20
Social and leisure 3.17 (1.22) 2.87 (1.11) .045
Extended family 2.05 (.52) 1.97 (.50) .34Page 10 of 12
(page number not for citation purposes)
BMC Psychiatry 2005, 5:10 http://www.biomedcentral.com/1471-244X/5/10SF-36 MH correlated significantly with most of such psy-
chiatric measures, and MH is currently used as a valid
measure for mental health in several studies [33].
This result could indicate that the other dimensions of the
SF-36 are less valid as measures of changes in mental
health of PD patients, or alternatively that most aspects of
QoL measured by the SF-36 do not change in PD patients
even if established psychiatric measures do.
The main strength of our study was that we were able
examine systematically various aspects of the QoL meas-
ured by the SF-36 in a clinically relevant sample of PD
patients at a POC which is a common setting for such
patients in psychiatry.
Our study had a number of weaknesses. The study groups
were small with limited statistical power, and there was a
considerable risk of type II errors. More significant differ-
ences as to the SF-36 dimensions could turn up in larger
samples. Although we put considerable efforts into loca-
tion of patients, we had a lower follow-up rate than we
had expected. However, the PD patients who did not
show up at follow-up did not differ much from those who
did. We cannot, therefore, generalize the discrepancy
observed between significant changes in established psy-
chiatric measures and lack of such changes in most of the
SF-36 dimensions of PD patients treated at a POC to
widely.
The same experienced psychiatrists did all the interviews
at baseline and follow-up. Although she was not involved
in any treatments, we cannot exclude an expectation bias
from her side.
We think that our study has to be considered an explora-
tory one. Our finding of a generally strongly reduced QoL
should be replicated in a PD sample with less comorbid
Axis I disorders, although their influence was limited. The
same is true for QoL as a valid measure for change in PD
patient, since it was not recommended as part of a stand-
ard outcome battery and was not used by major treatment
studies of PD patients. However, our study confirmed that
the SF-36 MH dimension seemed to be a valid psychiatric
measure in our PD patient sample.
Conclusion
In this study of the QoL in PD patients seen at an ordinary
POC, we found that the PD patients had significantly
lower mean scores on all the SF-36 dimensions compared
to age- and gender-adjusted norm data. This is in accord-
ance with the SF-36 measurements of other major diag-
nostic groups of mental disorders. Although the SF-36
dimensions correlated considerably with established psy-
chiatric measures in our PD patients, they did not show
the same significant changes over time as the established
measures. The use of QoL measures like the SF-36 as an
outcome measure in PD patients is in need of further
investigation.
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